Lactobacillus reuteri ATCC PTA 6475 is a specific strain of probiotic bacteria. It is a Lactobacillus bacterium, known for producing lactic acid. This particular strain was originally isolated from the breast milk of a Finnish woman. It has since become a subject of scientific interest due to its potential health applications.
Unique Health Applications
Lactobacillus reuteri ATCC PTA 6475 has been investigated for its influence on various aspects of human health. Research focuses on its anti-inflammatory properties. This strain has shown potential in maintaining a healthy gut microbiota, which is linked to several bodily functions.
Beyond general gut health, studies suggest specific benefits for bone metabolism. Supplementation has shown potential to prevent gut microbiota degradation and inflammatory status in older women with low bone mineral density. Animal studies show its potential to increase bone density and reduce bone loss.
The strain has also been explored for its effects on hormonal balance and skin quality in animal models, showing potential to improve levels of testosterone and oxytocin, and enhance skin appearance. Research has also looked into its role in oral health, where it has been observed to reduce levels of bacteria associated with dental caries and periodontal pathogens.
Mechanisms of Action
Lactobacillus reuteri ATCC PTA 6475 exerts its beneficial effects through several biological processes. It can colonize the gastrointestinal tract, surviving stomach acid to establish itself in the digestive system. This colonization allows it to interact with the host’s immune system.
The strain modulates inflammatory responses. It reduces levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β, potentially through histamine receptor H2 activation. Research also indicates its ability to influence the production of specific T cells, which play a role in regulating the immune system.
L. reuteri ATCC PTA 6475 can produce specific molecules that contribute to its actions. It produces substances like lactobacillic acid, a fatty acid that has been shown to suppress osteoclast differentiation, which is relevant to bone health.
Sourcing and Consumption
Lactobacillus reuteri ATCC PTA 6475 is primarily available in probiotic supplements. These products often come in forms such as chewable tablets, capsules, or powders. This strain is frequently combined with other Lactobacillus reuteri strains, such as DSM 17938, in commercial probiotic formulations.
Typical research doses for Lactobacillus reuteri strains, including ATCC PTA 6475, range from 1 billion to 100 billion colony-forming units (CFU) per day. It is advised to take these supplements with food, but avoiding hot beverages is recommended to protect the viability of the live bacteria. Storing products containing L. reuteri ATCC PTA 6475 in cool conditions helps maintain bacterial viability.
Important Considerations
While Lactobacillus reuteri ATCC PTA 6475 is considered safe for most individuals, including healthy adults and children, some mild side effects can occur. These may include gastrointestinal discomfort such as gas, bloating, or mild abdominal pain, especially when first starting supplementation. Diarrhea can also occur, particularly with higher doses.
Individuals with compromised immune systems, such as those undergoing chemotherapy or with HIV infection, should exercise caution and consult a healthcare professional before using probiotics. Although rare, serious infections like bacteremia are possible in these populations. It is also advisable to discuss any new supplement regimen with a doctor, especially for those with existing health conditions or taking other medications, including antibiotics or immunosuppressants, as interactions may occur.